The regulator is allowing generic makers room on the OTC contraceptive shelf.
The drugmaker may be able to settle around 3,800 cases for $100 million.
The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.